Scientists have imaged the toxic clumps and fibres made by expanded huntingtin with cutting-edge microscopes, helping us to understand the exact way they can be assembled and how their structure could ...

In Huntington’s disease research, biomarkers are the secret weapon for spotting treatment effects. A new blood study uncovers two proteins, CAP1 and CAPZB, that, with additional work, could help track ...

Some childhood experiences stay with us, quietly shaping how we feel as adults. For those raised in families with Huntington’s disease, this new study helps make sense of those feelings, and reminds ...

Huntington’s disease doesn’t just damage the brain, it also breaks down muscles and fat, and disrupts nutrition early on. New work suggests there’s a hidden physical decline in early HD, so monitoring ...

We know that lifestyle factors – like exercise, sleep, and alcohol consumption – can have an impact on the onset of Huntington’s disease (HD). Another lifestyle factor that people frequently wonder ...

Sleep is more than a nightly recharge, it is fundamental to brain health. A landmark 12-year study tracking people with the gene for Huntington’s disease (HD) suggests how specific sleep disturbances ...

A recent study used miniature 3D brain models grown from stem cells to explore how the genetic change that causes Huntington’s disease (HD) might impact early brain development, before neurons even ...

A recent publication discusses a non-invasive way of measuring levels of expanded HTT protein in the brain, using an imaging tool called a PET tracer. The results were variable, but there’s still a ...

Huntington’s disease disrupts genetic "traffic lights," keeping genes green when they should be red. These genetic traffic jams may act to speed brain cell aging and faulty traffic cops fail to stop ...

Imagine the gene that causes Huntington’s disease (HD) as a vast river. At its source is the CAG repeat – a genetic letter code that dictates how the river will flow. As the river moves downstream, it ...

On May 5th, PTC Therapeutics released results from their ongoing Phase 2 PIVOT-HD clinical trial for PTC-518, now called votoplam. Excitingly, they announced that this trial met its primary endpoint – ...